$3.6M Hemispherx Securities Settlement Gets Final OK

Law360, New York (February 15, 2011, 2:31 PM EST) -- A federal judge has given final approval to a $3.6 million settlement between Hemispherx Biopharma Inc. and a class of plaintiffs who alleged the company misled investors on the approval status of chronic fatigue syndrome drug Ampligen.

Judge Paul S. Diamond of the U.S. District Court for the Eastern District of Pennsylvania gave the final go-ahead for the settlement in the consolidated class action Monday. The class includes all investors who purchased Hemispherx stock between Feb. 18, 2009, and Dec. 1, 2009.

The consolidated class action...
To view the full article, register now.